ArticleJACC. Advances2026
Sex-Specific and Time-Dependent Outcomes After TAVR Versus SAVR: A Meta-Analysis of Randomized Trials.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex differences in outcomes after transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) have been reported, but their variation over time and across surgical risk strata remains uncertain.
objectivesThe objective of the study was to evaluate sex-specific and time-dependent outcomes of TAVR vs SAVR and the influence of baseline surgical risk.
methodsPubMed, Embase, and Cochrane Central Register of Controlled Trials were searched through January 18, 2026. Randomized controlled trials reporting sex-stratified, mortality-inclusive primary endpoints with ≥1-year follow-up were included. Pooled risk ratios (RRs) were estimated using random-effects models, with prespecified analyses by sex and surgical risk and exploratory meta-regression.
resultsNine trials (N = 9,583; 44.2% women) were included. In women, TAVR was associated with lower risk at 1 and 2 years vs SAVR (1 year: RR: 0.67; 95% CI: 0.55-0.81; 2 years: RR: 0.80; 95% CI: 0.69-0.94), with no significant difference at 5 years (RR: 1.03; 95% CI: 0.89-1.18). In men, no significant differences were observed across time points. By surgical risk, early benefit with TAVR in women was more evident in intermediate-high-risk patients, whereas at 5 years a higher risk with TAVR was observed in men; no clear sex differences were seen in low-risk patients. Meta-regression showed no significant effect modification by age, surgical risk, or atrial fibrillation prevalence.
conclusionsOutcomes after aortic valve replacement vary by sex, surgical risk, and time. TAVR was associated with early benefit in women, particularly in intermediate-high-risk patients, with convergence over longer follow-up, whereas men showed no significant differences across time points, with higher risk observed with TAVR at 5 years in intermediate-high-risk patients. (Sex Differences in Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement: An Updated Meta-Analysis of Randomized Controlled Trials; CRD420261287967).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.